Andere talen Pacira BioSciences, Inc.

Aandelen

PCRX

US6951271005

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 21:00:00 14-03-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
22,87 ^USD	+0,79%		-2,14%	+21,39%

14/03	Pacira BioSciences bevestigt ontvangst van voordrachten voor bestuurders van DOMA Perpetual	RE
12/03	Pacira BioSciences, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-12-2025 08:00 AM

Andere talen

Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual	14/03
DOMA Perpetual Nominates Candidates for the Board of Pacira BioSciences	14/03
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual	14/03
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual	14/03
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences	14/03
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira	13/03
Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX	13/03
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & Korsinsky	12/03
PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX	11/03
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX	11/03
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX	10/03
PACIRA BIOSCIENCES CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX	08/03
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline	06/03
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira	05/03
PCRX Deadline: PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit	04/03
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX	04/03
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX	03/03
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX	03/03
Pacira BioSciences : 4Q 2024 Earnings Presentation	28/02
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	28/02
Pacira: Q4 Earnings Snapshot	27/02
Earnings Flash (PCRX) Pacira BioSciences Posts Q4 Adjusted EPS $0.91, vs. FactSet Est of $0.84	27/02
Earnings Flash (PCRX) Pacira BioSciences Reports Q4 Revenue $187.3M, vs. FactSet Est of $184.7M	27/02
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	27/02

f5d35.5KnicrLCWPr8JC0oULP9y-xb-MSGKTff3-pwc7zIzjw.puyDFIK3EqXLcVxGJfClqtoZkvDoEWOHqp8iGuSMukaDy7Qw2PBqo4ZuSg

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pacira BioSciences, Inc.

Aandelen

PCRX

US6951271005

Farmaceutische producten

Andere talen

Filters